MedTrace Logo

Nifedipine Extended-Release in Patients With Mild or Moderate Hypertension

NCT07448506 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-08-13

No results posted yet for this study

Summary

To evaluate the efficacy of Nifedipine 30mg Extended-Release Richmond versus Nifedipine 30mg extended-release with a current registration in Colombia, measured by the proportion of patients with controlled blood pressure in adult patients diagnosed with mild or moderate hypertension at week 8 of follow-up.

Conditions

  • High Blood Pressure (& [Essential Hypertension])

Interventions

DRUG

Treatment with Nifedipine 30 mg Extended-Release (Richmond)

30 mg administered orally once daily

DRUG

Comparator Nifedipine 30 mg Extended-Release

30 mg administered orally once daily.

Sponsors & Collaborators

  • Laboratorios Richmond Colombia SAS

    collaborator INDUSTRY

  • Laboratorios Richmond S.A.C.I.F.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-09
Primary Completion
2025-04-15
Completion
2025-08-13

Countries

  • Colombia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07448506 on ClinicalTrials.gov